Petros Pharmaceuticals Strengthens Balance Sheet with Subsidiary Deconsolidation

“`html

Petros Pharmaceuticals Announces Strategic Deconsolidation to Enhance Financial Position

New york, NY – June 25, 2025 – Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) today announced a strategic move to deconsolidate its subsidiary, Metuchen Pharmaceuticals LLC, including its subsidiaries Timm Medical Technologies, Inc.and Pos-T-Vac,LLC. This significant change,effective at the end of June 2025,is projected to substantially improve Petros’ financial health.

Deconsolidation Details And Financial Impact

The deconsolidation of metuchen Pharmaceuticals is anticipated to bolster Petros Pharmaceuticals’ financial standing. Specifically, it is indeed expected to increase stockholders’ equity while considerably reducing the company’s consolidated debt. This strategic initiative reflects a broader corporate realignment aimed at optimizing operations and improving financial versatility.

following the completion of the deconsolidation, Petros anticipates a stronger balance sheet. This improved financial position is crucial for meeting the minimum stockholders’ equity requirements necessary for continued listing on the Nasdaq Capital Market.

Nasdaq Compliance And Future Prospects

Petros Pharmaceuticals is currently appealing Nasdaq’s recent decision regarding the potential delisting of its common stock. The company believes that this deconsolidation, along with other internal strategies, indicates considerable progress towards regaining full compliance with Nasdaq’s listing standards.

Fady Boctor, President And Chief Commercial Officer of Petros Pharmaceuticals, emphasized the importance of this decision. “Deconsolidating Metuchen is a strategic and necessary step

What are the specific KPIs Petros Pharmaceuticals will use to measure the success of the Metuchen Pharmaceuticals deconsolidation?

In a strategic move poised to reshape its financial landscape, Petros Pharmaceuticals announced the deconsolidation of its subsidiary, Metuchen Pharmaceuticals, on June 25, 2025. This pivotal decision is designed to bolster Petros Pharmaceuticals’ financial health and strategic positioning within the self-care market.

Deconsolidation Explained: The Core Concept

Deconsolidation, at its core, is a financial maneuver where a parent company removes a subsidiary from its consolidated financial statements. This means the subsidiary’s assets, liabilities, revenues, and expenses are no longer integrated into the parent company’s financial reports. The primary goal is frequently enough to streamline operations, reduce debt, and enhance financial ratios.

Key Benefits of Deconsolidation

The benefits of deconsolidation can be manifold, including:

• Improved Balance Sheet Metrics: Reducing liabilities and possibly increasing assets, leading to a healthier debt-to-equity ratio. Focusing on Key Performance Indicators (KPIs) can help measure the effects of deconsolidation.
• Enhanced Equity Position: The deconsolidation can lead to an increase in the company’s equity value, positively influencing investor confidence.
• Strategic Versatility: Allowing Petros Pharmaceuticals to concentrate on core business activities, such as innovation within the self-care market.

Financial Impact and Future Projections

The actual financial impact of the Metuchen Pharmaceuticals deconsolidation will be detailed in Petros Pharmaceuticals’ future filings with the Securities and Exchange Commission (SEC). However, several potential outcomes can be anticipated based on the general principles of deconsolidation.

Expected Financial Effects

While the specifics are pending, potential financial outcomes of the deconsolidation can include:

• Reduction in Total Liabilities: Removing Metuchen’s debts from Petros’ balance sheet.
• Potential Asset Adjustments: Changes in the overall asset base, dependent on the transaction terms.
• Impact on Net income: Future financial reports will show these changes clearly.

Petros Pharmaceuticals: A Market Innovator

Petros Pharmaceuticals aims to become a leader in the thriving $38 billion self-care market. By deconsolidating Metuchen, the pharmaceutical company is strategically repositioning itself to achieve this aspiring goal.

Focus on the Self-Care Market

Key aspects include:

• Market Growth and Trends: The self-care market is expanding, encompassing numerous wellness products.
• Innovation and Product Growth: Focus on developing new products within the self-care domain.
• Strategic Positioning: Aiming for an beneficial competitive position in the market.